Policy / Pricing FDA accelerated approval path needs improvement, says ICER PharmaphorumThe FDA's accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER.Policy / PricingRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaphorum The FDA’s accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER. Policy / PricingRead full story Post navigation Previous: Lilly says Foundayo safety confirmed in ACHIEVE-4 trialNext: Obesity’s explosive growth continues as Q1 deals exceed total 2025 value Related Stories Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged pharminent May 13, 2026 Policy / Pricing EU agrees plan to tackle essential medicine shortages pharminent May 12, 2026 Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) pharminent May 12, 2026
